Details

Autor(en) / Beteiligte

• Ju, Wu‐tong
• Liu, Ying
• Wang, Li‐zhen
• Li, Jiang
• Ren, Guo‐xing
• Sun, Jian
• Tu, Wen‐yong
• Hu, Yong‐jie
• Ji, Tong
• Yang, Wen‐jun
• Li, Jun
• He, Yue
• Wang, Yan‐an
• Zhang, Chen‐ping
• Zhong, Lai‐ping
• Zhang, Zhi‐yuan

Titel

Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome

Ist Teil von

• Cancer communications (London, England), 2021-03, Vol.41 (3), p.279-283

Ort / Verlag

United States: John Wiley & Sons, Inc

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Wiley Online Library Journals Frontfile Complete

Beschreibungen/Notizen

• Due to the limited sample size of the clinical N2 group, our retrospective subgroup analyses were not sufficient to guide further treatment plan until further demonstrated by convincing studies. Besides clinical indicators, we also focused on the predictive effect of pathological response after induction chemotherapy. The pCR rate was consistent with another trial investigating split TPF induction chemotherapy regimen in oral and oropharyngeal squamous cell cancer, in which pCR rate was 31.5% (17/54) [ 6]. Since the pCR rate of induction chemotherapy was relatively low, major pathological response (MPR) or FPR, which were both defined as ≤10% of residual viable tumor after induction chemotherapy, were used as surrogate criteria of pathological response evaluation and endpoints for survival [ 3]. Attempts to intensify TPF with cetuximab to increase efficacy on HNSCC demonstrated no significant effectiveness but was rather toxic [ 7]. Since immunotherapy demonstrated efficacy in HNSCC and some other cancers, such as esophageal squamous cell carcinoma and triple-negative breast cancer, with excellent tolerability, it has been currently tested in combination with chemotherapy [ 8, 9]. [...]TPF induction chemotherapy failed to improve the survival of unselected patients with locally advanced OSCC.